336 related articles for article (PubMed ID: 11090080)
1. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
[TBL] [Abstract][Full Text] [Related]
2. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins.
Parker JE; Fishlock KL; Mijovic A; Czepulkowski B; Pagliuca A; Mufti GJ
Br J Haematol; 1998 Dec; 103(4):1075-82. PubMed ID: 9886323
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes.
Boudard D; Vasselon C; Berthéas MF; Jaubert J; Mounier C; Reynaud J; Viallet A; Chautard S; Guyotat D; Campos L
Am J Hematol; 2002 Jun; 70(2):115-25. PubMed ID: 12111784
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
6. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
7. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
Span LF; Dar SE; Shetty V; Mundle SD; Broady-Robinson L; Alvi S; Raymakers RA; de Witte T; Raza A
Leukemia; 1998 Nov; 12(11):1685-95. PubMed ID: 9823942
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
9. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes.
Merchant SH; Gonchoroff NJ; Hutchison RE
Cytometry; 2001 Feb; 46(1):28-32. PubMed ID: 11241504
[TBL] [Abstract][Full Text] [Related]
11. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
12. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
13. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
14. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
Mihara K; Chowdhury M; Nakaju N; Hidani S; Ihara A; Hyodo H; Yasunaga S; Takihara Y; Kimura A
Blood; 2006 Jan; 107(1):305-8. PubMed ID: 16160010
[TBL] [Abstract][Full Text] [Related]
15. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro.
Bouscary D; Chen YL; Guesnu M; Picard F; Viguier F; Lacombe C; Dreyfus F; Fontenay-Roupie M
Exp Hematol; 2000 Jul; 28(7):784-91. PubMed ID: 10907640
[TBL] [Abstract][Full Text] [Related]
16. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
[TBL] [Abstract][Full Text] [Related]
17. Increased apoptosis in mononucleated cells but not in CD34+ cells in blastic forms of myelodysplastic syndromes.
Berger G; Hunault-Berger M; Rachieru P; Fontenay-Roupie M; Baranger L; Ifrah N; Zandecki M
Hematol J; 2001; 2(2):87-96. PubMed ID: 11424000
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression.
Davis RE; Greenberg PL
Leuk Res; 1998 Sep; 22(9):767-77. PubMed ID: 9716007
[TBL] [Abstract][Full Text] [Related]
19. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
Varma N; Varma S
Indian J Pathol Microbiol; 2008; 51(1):97-101. PubMed ID: 18417875
[TBL] [Abstract][Full Text] [Related]
20. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
